CERo Therapeutics secures key patents for cancer therapy

SOUTH SAN FRANCISCO - CERo Therapeutics Holdings, Inc. (NASDAQ:CERO), a biotechnology firm specializing in immunotherapy with a current market capitalization of $2.4 million, has expanded its intellectual property portfolio with the granting of two U.S. patents and the allowance of one European patent application. The company’s stock, currently trading near its 52-week low of $0.43, has seen significant volatility in recent months. According to InvestingPro analysis, CERo maintains a positive aspect by holding more cash than debt on its balance sheet, though its overall financial health score indicates challenges ahead. These developments are expected to strengthen the company’s proprietary position in engineered T cell therapeutics.

On May 6, 2025, the U.S. Patent and Trademark Office (USPTO) granted U.S. Patent No. 12,291,557, which covers design aspects of CER-1236, CERo’s lead compound. This patent pertains to a chimeric TIM4 receptor that includes a TIM4 binding domain and canonical T cell signaling domains.

Following this, the European Patent Office allowed European Patent Application No. 1882166.7 on May 16, 2025. This application protects a chimeric engulfment receptor with a TIM4 binding domain and TLR2 signaling domain, which is part of the design of CER-1236. These claims have already been granted in the U.S., Japan, and China.

Additionally, the USPTO granted U.S. Patent No. 12,303,551 on May 20, 2025. This patent provides coverage for combination cellular immunotherapy compositions and their use in cancer treatment, specifically relating to CER-1236. It covers the combination of a chimeric engulfment receptor CD4+ T cell with either a chimeric antigen receptor CD8+ T cell or T cell receptor CD8+ T cell.

With these new patents, CERo’s intellectual property now comprises nine patent families and extends protection until 2042 in the United States. Collectively, the company’s technology is supported by 18 issued patents and allowed patent applications internationally.

CEO Chris Ehrlich expressed confidence in the company’s continued growth, citing the importance of the patents in differentiating CERo’s technology from other cell therapies. He also highlighted the recognition of the CER-T technology’s novelty by patent offices as a validation of its innovative and therapeutic potential. However, InvestingPro data reveals the company faces near-term financial challenges, with analysts projecting an EPS of -$2.82 for fiscal year 2025. Subscribers to InvestingPro can access 12 additional key insights about CERo’s financial position and market outlook.

CERo is currently conducting clinical trials for its lead product candidate CER-1236 for hematological malignancies and plans to initiate human trials for ovarian and non-small cell lung cancers. With the next earnings report expected on August 14, 2025, investors are closely monitoring the company’s progress. InvestingPro analysis shows analyst price targets ranging from $3 to $11, suggesting potential upside despite current market challenges. Get comprehensive financial analysis and real-time alerts with an InvestingPro subscription.

This information is based on a press release statement from CERo Therapeutics Holdings, Inc. The company’s forward-looking statements are not historical facts and involve risks and uncertainties that could cause actual results to differ materially. CERo has provided these statements as projections and forecasts and not as guarantees of future performance.

In other recent news, CERo Therapeutics Holdings, Inc. has initiated a Phase 1 clinical trial for its lead product candidate, CER-1236, targeting acute myeloid leukemia (AML). The trial is being conducted at multiple sites, including the Sarah Cannon Research Institute and the Colorado Blood Cancer Institute, with patient enrollment currently underway. The study will focus on assessing the safety and preliminary efficacy of CER-1236 in AML patients, including those with relapsed or refractory disease and specific genetic mutations. This development marks a significant milestone for CERo as it explores the potential of its Chimeric Engulfment Receptor T cells (CER-T) technology.

In another recent development, CERo Therapeutics has regained compliance with Nasdaq’s minimum stockholders’ equity requirement, following financial maneuvers such as a private placement of Series D Preferred Stock and a public offering. Additionally, Maxim Group has initiated coverage of CERo Therapeutics with a Buy rating, setting a price target of $3.00. The analyst from Maxim Group highlighted the potential of CERo’s CER-T technology in treating both liquid and solid tumors. These recent developments underscore CERo’s commitment to advancing its innovative therapies and maintaining its financial standing.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.